Hypercholesterolemia, Familial Clinical Trial
Official title:
Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®
Protein convertase subtilisin kexin type 9 (PCSK-9) inhibitors demonstrated efficacy in cholesterol reduction and in the prevention of cardiovascular events. The investigators will evaluate changes in lipid profile, oxidation markers and subclinical atherosclerosis in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with a PCSK-9 inhibitor, Evolocumab®.
Several studies emphasize the role of high levels of low-density lipoprotein cholesterol (LDL-C) as the main causative factor in atherosclerosis development. Among patients with hypercholesterolemia, those with very high levels of LDL-C exhibit increased prevalence of subclinical atherosclerosis and a higher atherosclerosis progression, thus leading to a significantly higher CV risk. Endothelial dysfunction is the earliest stage of the atherosclerotic process and even a trigger of CV events. Flow-mediated dilation (FMD) is widely accepted as an accurate and non-invasive method to assess vascular reactivity and, in turn, as a surrogate marker of subclinical atherosclerosis and an independent predictor of CV events. It's well known that hypercholesterolemia has been associated with decreased endothelial function and increased oxidative stress. Although statin treatment represented for years the gold standard as lipid lowering therapy, the target LDL-C is not always achieved, mainly among patients with very high levels of LDL-C. More recently, PCSK-9 inhibitors demonstrated efficacy in LDL-C reduction, in the prevention from CV events and in atherosclerotic burden regression. Some data showed an effect of PCSK-9 inhibitors on endothelial function, but no evidence is available on effect on LDL subfractions. Small dense LDL (sd-LDL) are considered an emerging risk factor for cardiovascular disease due to a greater atherogenic potential [ ] and are important markers for predicting CV risk. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00384293 -
Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)
|
Phase 3 | |
Completed |
NCT04722068 -
Regeneron 1331 Kinetics Sub-Study HoFH
|
N/A | |
Completed |
NCT04118348 -
Evaluating the Efficacy of Pediatric Lipid Screening Alerts
|
N/A | |
Completed |
NCT00000594 -
NHLBI Type II Coronary Intervention Study
|
Phase 3 | |
Completed |
NCT04526457 -
Is Family Screening Improved by Genetic Testing of Familial Hypercholesterolemia
|
N/A | |
Completed |
NCT01753232 -
Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter
|
N/A | |
Completed |
NCT03018678 -
Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
|
||
Completed |
NCT00134511 -
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|
Phase 3 | |
Completed |
NCT00134485 -
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
|
Phase 3 | |
Recruiting |
NCT04073797 -
PET Imaging of Inflammation and Lipid Lowering Study
|
N/A | |
Terminated |
NCT01583647 -
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
|
Phase 1 | |
Completed |
NCT00515307 -
Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia
|
Phase 1 | |
Recruiting |
NCT04656028 -
Genetic Testing and Motivational Counseling for FH
|
N/A | |
Terminated |
NCT00092833 -
Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)
|
Phase 3 | |
Active, not recruiting |
NCT04837638 -
Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
|
||
Completed |
NCT00280995 -
Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
|
Phase 2 | |
Completed |
NCT06231459 -
Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia
|
Phase 4 | |
Completed |
NCT01524289 -
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
|
Phase 3 | |
Completed |
NCT00281008 -
Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
|
Phase 2 | |
Recruiting |
NCT03989167 -
Clinical Decision Support for Familial Hypercholesterolemia
|
N/A |